These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

194 related articles for article (PubMed ID: 28691344)

  • 1. Combined tumor genomic profiling and exome sequencing in a breast cancer family implicates ATM in tumorigenesis: A proof of principle study.
    Bubien V; Bonnet F; Dupiot-Chiron J; Barouk-Simonet E; Jones N; de Reynies A; MacGrogan G; Sevenet N; Letouzé E; Longy M
    Genes Chromosomes Cancer; 2017 Nov; 56(11):788-799. PubMed ID: 28691344
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Almost 2% of Spanish breast cancer families are associated to germline pathogenic mutations in the ATM gene.
    Tavera-Tapia A; Pérez-Cabornero L; Macías JA; Ceballos MI; Roncador G; de la Hoya M; Barroso A; Felipe-Ponce V; Serrano-Blanch R; Hinojo C; Miramar-Gallart MD; Urioste M; Caldés T; Santillan-Garzón S; Benitez J; Osorio A
    Breast Cancer Res Treat; 2017 Feb; 161(3):597-604. PubMed ID: 27913932
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Morphology and genomic hallmarks of breast tumours developed by ATM deleterious variant carriers.
    Renault AL; Mebirouk N; Fuhrmann L; Bataillon G; Cavaciuti E; Le Gal D; Girard E; Popova T; La Rosa P; Beauvallet J; Eon-Marchais S; Dondon MG; d'Enghien CD; Laugé A; Chemlali W; Raynal V; Labbé M; Bièche I; Baulande S; Bay JO; Berthet P; Caron O; Buecher B; Faivre L; Fresnay M; Gauthier-Villars M; Gesta P; Janin N; Lejeune S; Maugard C; Moutton S; Venat-Bouvet L; Zattara H; Fricker JP; Gladieff L; Coupier I; ; ; ; Chenevix-Trench G; Hall J; Vincent-Salomon A; Stoppa-Lyonnet D; Andrieu N; Lesueur F
    Breast Cancer Res; 2018 Apr; 20(1):28. PubMed ID: 29665859
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Germline mutations of breast cancer susceptibility genes through expanded genetic analysis in unselected Colombian patients.
    Sierra-Díaz DC; Morel A; Fonseca-Mendoza DJ; Bravo NC; Molano-Gonzalez N; Borras M; Munevar I; Lema M; Idrobo H; Trujillo D; Serrano N; Orduz AI; Lopera D; González J; Rojas G; Londono-De Los Ríos P; Manneh R; Cabrera R; Rubiano W; de la Peña J; Quintero MC; Mantilla W; Restrepo CM
    Hum Genomics; 2024 Jun; 18(1):68. PubMed ID: 38890714
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Whole-exome sequencing of Finnish hereditary breast cancer families.
    Määttä K; Rantapero T; Lindström A; Nykter M; Kankuri-Tammilehto M; Laasanen SL; Schleutker J
    Eur J Hum Genet; 2016 Jan; 25(1):85-93. PubMed ID: 27782108
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The Landscape of Somatic Genetic Alterations in Breast Cancers From ATM Germline Mutation Carriers.
    Weigelt B; Bi R; Kumar R; Blecua P; Mandelker DL; Geyer FC; Pareja F; James PA; ; Couch FJ; Eccles DM; Blows F; Pharoah P; Li A; Selenica P; Lim RS; Jayakumaran G; Waddell N; Shen R; Norton L; Wen HY; Powell SN; Riaz N; Robson ME; Reis-Filho JS; Chenevix-Trench G
    J Natl Cancer Inst; 2018 Sep; 110(9):1030-1034. PubMed ID: 29506079
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Identification of candidate cancer predisposing variants by performing whole-exome sequencing on index patients from BRCA1 and BRCA2-negative breast cancer families.
    Shahi RB; De Brakeleer S; Caljon B; Pauwels I; Bonduelle M; Joris S; Fontaine C; Vanhoeij M; Van Dooren S; Teugels E; De Grève J
    BMC Cancer; 2019 Apr; 19(1):313. PubMed ID: 30947698
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Exome sequencing of germline DNA from non-BRCA1/2 familial breast cancer cases selected on the basis of aCGH tumor profiling.
    Hilbers FS; Meijers CM; Laros JF; van Galen M; Hoogerbrugge N; Vasen HF; Nederlof PM; Wijnen JT; van Asperen CJ; Devilee P
    PLoS One; 2013; 8(1):e55734. PubMed ID: 23383274
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Detection of ATM germline variants by the p53 mitotic centrosomal localization test in BRCA1/2-negative patients with early-onset breast cancer.
    Prodosmo A; Buffone A; Mattioni M; Barnabei A; Persichetti A; De Leo A; Appetecchia M; Nicolussi A; Coppa A; Sciacchitano S; Giordano C; Pinnarò P; Sanguineti G; Strigari L; Alessandrini G; Facciolo F; Cosimelli M; Grazi GL; Corrado G; Vizza E; Giannini G; Soddu S
    J Exp Clin Cancer Res; 2016 Sep; 35(1):135. PubMed ID: 27599564
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Rare germline large rearrangements in the BRCA1/2 genes and eight candidate genes in 472 patients with breast cancer predisposition.
    Rouleau E; Jesson B; Briaux A; Nogues C; Chabaud V; Demange L; Sokolowska J; Coulet F; Barouk-Simonet E; Bignon YJ; Bonnet F; Bourdon V; Bronner M; Caputo S; Castera L; Delnatte C; Delvincourt C; Fournier J; Hardouin A; Muller D; Peyrat JP; Toulas C; Uhrhammer N; Vidal V; Stoppa-Lyonnet D; Bieche I; Lidereau R
    Breast Cancer Res Treat; 2012 Jun; 133(3):1179-90. PubMed ID: 22476849
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Novel germline mutations in breast cancer susceptibility genes BRCA1, BRCA2 and p53 gene in breast cancer patients from India.
    Hedau S; Jain N; Husain SA; Mandal AK; Ray G; Shahid M; Kant R; Gupta V; Shukla NK; Deo SS; Das BC
    Breast Cancer Res Treat; 2004 Nov; 88(2):177-86. PubMed ID: 15564800
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Frequency of the ATM IVS10-6T-->G variant in Australian multiple-case breast cancer families.
    Lindeman GJ; Hiew M; Visvader JE; Leary J; Field M; Gaff CL; Gardner RJ; Trainor K; Cheetham G; Suthers G; Kirk J
    Breast Cancer Res; 2004; 6(4):R401-7. PubMed ID: 15217508
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prevalence of deleterious ATM germline mutations in gastric cancer patients.
    Huang DS; Tao HQ; He XJ; Long M; Yu S; Xia YJ; Wei Z; Xiong Z; Jones S; He Y; Yan H; Wang X
    Oncotarget; 2015 Dec; 6(38):40953-8. PubMed ID: 26506520
    [TBL] [Abstract][Full Text] [Related]  

  • 14. ATM germline mutations in women with familial breast cancer and a relative with haematological malignancy.
    Paglia LL; Laugé A; Weber J; Champ J; Cavaciuti E; Russo A; Viovy JL; Stoppa-Lyonnet D
    Breast Cancer Res Treat; 2010 Jan; 119(2):443-52. PubMed ID: 19404735
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Challenges in Interpreting Germline Mutations in BARD1 and ATM in Breast and Ovarian Cancer Patients.
    DeLeonardis K; Sedgwick K; Voznesensky O; Matloff E; Hofstatter E; Balk S; Tung N
    Breast J; 2017 Jul; 23(4):461-464. PubMed ID: 28139868
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Double heterozygotes among breast cancer patients analyzed for BRCA1, CHEK2, ATM, NBN/NBS1, and BLM germ-line mutations.
    Sokolenko AP; Bogdanova N; Kluzniak W; Preobrazhenskaya EV; Kuligina ES; Iyevleva AG; Aleksakhina SN; Mitiushkina NV; Gorodnova TV; Bessonov AA; Togo AV; Lubiński J; Cybulski C; Jakubowska A; Dörk T; Imyanitov EN
    Breast Cancer Res Treat; 2014 Jun; 145(2):553-62. PubMed ID: 24800916
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Two PALB2 germline mutations found in both BRCA1+ and BRCAx familial breast cancer.
    Downs B; Kim YC; Xiao F; Snyder C; Chen P; Fleissner EA; Becirovic D; Wen H; Sherman S; Cowan KH; Lynch HT; Wang SM
    Breast Cancer Res Treat; 2015 May; 151(1):219-24. PubMed ID: 25833210
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinicopathologic Profile of Breast Cancer in Germline ATM and CHEK2 Mutation Carriers.
    Toss A; Tenedini E; Piombino C; Venturelli M; Marchi I; Gasparini E; Barbieri E; Razzaboni E; Domati F; Caggia F; Grandi G; Combi F; Tazzioli G; Dominici M; Tagliafico E; Cortesi L
    Genes (Basel); 2021 Apr; 12(5):. PubMed ID: 33919281
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Next-generation sequencing in familial breast cancer patients from Lebanon.
    Jalkh N; Chouery E; Haidar Z; Khater C; Atallah D; Ali H; Marafie MJ; Al-Mulla MR; Al-Mulla F; Megarbane A
    BMC Med Genomics; 2017 Feb; 10(1):8. PubMed ID: 28202063
    [TBL] [Abstract][Full Text] [Related]  

  • 20. p53 inactivation is a rare event in familial breast tumors negative for BRCA1 and BRCA2 mutations.
    Sensi E; Tancredi M; Aretini P; Cipollini G; Naccarato AG; Viacava P; Bevilacqua G; Caligo MA
    Breast Cancer Res Treat; 2003 Nov; 82(1):1-9. PubMed ID: 14672397
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.